Iovance Biotherapeutics (IOVA) Cash & Current Investments (2010 - 2026)

Iovance Biotherapeutics (IOVA) has reported Cash & Current Investments for 16 consecutive years, with $313.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments fell 12.86% year-over-year to $313.4 million; the TTM figure through Mar 2026 stood at $313.4 million (down 12.86% YoY), while the FY2025 annual figure was $297.0 million, down 8.28% from the prior year.
• Cash & Current Investments grew to $313.4 million in Q1 2026 per IOVA's latest filing, from $297.0 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $626.3 million in Q1 2023 and bottomed at $164.2 million in Q3 2024.
• Historically, Cash & Current Investments has averaged $347.2 million across 5 years, with a median of $323.8 million in 2024.
• Annual changes were most pronounced in 2024 — Cash & Current Investments slumped 54.56% — and 2025, when it soared 83.21%.
• Iovance Biotherapeutics' Cash & Current Investments stood at $471.8 million in 2022, then plunged by 40.69% to $279.9 million in 2023, then climbed by 15.69% to $323.8 million in 2024, then decreased by 8.28% to $297.0 million in 2025, then rose by 5.54% to $313.4 million in 2026.
• Business Quant data shows IOVA's Cash & Current Investments at $313.4 million in Q1 2026, $297.0 million in Q4 2025, and $300.8 million in Q3 2025.